Closing Reception Sponsor:





Current session postings reflect confirmed speakers only.


Biotechnology State of the Industry Report: Beyond Borders
8:30am – 9:45am

At 31-years old, biotechnology has reached a point where it has "come of age" and now it's on to the maturing years. We've seen evidence of strengthening pipelines, revenue growth, and progress towards profitability. This is often when challenges emerge that are the result of success. Challenges born from the convergence in time of innovative new products, newly profitable companies, and escalating regulatory challenges.

"Beyond Borders", an annual analysis of life sciences industry published by Ernst & Young, brings together biotech and pharmaceutical executives as well as global financial experts to analyze the economic motivation, political environment, and cultural diversity that shapes revenue and investment numbers around the world.

Reflecting on success of 2006 and looking ahead for 2007-2008, Scott Morrison will offer unique, global insight into past and future of the industry.

In his “Beyond Borders” address Scott Morrison will discuss the 2006 industry financials, including 12 months of company financial data and market caps for the US, Europe, Canada and Asia; and historical industry performance over the past 20 years; offer an analysis of key activities taking place in various industry sectors including: healthcare, diagnostics, nutraceuticals, agbio, and industrial biotechnology; provide industry highlights including: new product approvals, advances in technology, scientific breakthroughs, regulatory challenges, business models, strategic partnering/M&A activity, as well as a thorough analysis of the finance and capital markets.

Keynote Speaker:

Scott Morrison
National Leader, Life Sciences, Ernst & Young LLP

Future of Life Sciences Space: Expansion or Consolidation?
12:45pm - 1:45pm

The biotech star is rising. With the ever-increasing demand for drugs to treat aging baby-boomers, venture capitalists are betting billions that biotech can come up with life saving formulas. In the process the biotech industry is also curing one of the nationwide problems plaguing America, unemployment, by adding thousands of high paying career opportunities every year.

While this explosive industry growth is evident, we may be witnessing a pattern by multinational biopharmaceutical companies investing in just a few research centers in the US.

Representatives of several global biopharma companies will discuss a fundamental question of whether we are witnessing expansion or consolidation of the biotech space and if in the near future are we heading towards just two remaining life sciences research “poles” – Massachusetts and Northern California.

Panel Moderator:

Steve Richardson
Senior Vice President, Regional Market Director - San Francisco Bay Area
Alexandria Real Estate Equities, Inc.

Keynote Panel:

Shawn Pixley
Director of Research and Development Planning, Amgen

Alan Sachs, MD, PhD
Vice President, RNA Therapeutics, Merck Research Laboratories/ Sirna Therapeutics

Shehnaaz Suliman, MD
Director, Corporate Development, Gilead Sciences, Inc.